rs113658888 - MROH1
Magnitude 4.5 · 1 study on file
Reported associations
-
Genetic factors associated with prostate cancer conversion from active surveillance to treatment - Unknown journal (n.d.) · Unknown authors · PubMed 34993496
ABSTRACT: Summary Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for PC, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of wh
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
prostate surveillance intensity with MROH1 T allele Moderate
T allele carriers show 2.1-fold increased hazard of progression from active surveillance to active treatment in prostate cancer.
Discuss with oncology/urology about more frequent PSA monitoring or imaging, or early treatment consideration.